News

The partnership will integrate Ocuco’s optical software solution, Acuitas 3, with Nextech’s Ophthalmic Platform.

Results showed an unequal distributions of these clinical trials among rural and low-income populations.

VX01-DR-201, is a phase 2, multicenter, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).

Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.

PYK-2101 is a focal hydrogel retinal sealant for use in patients undergoing surgery for a detached retina.

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after the COAST trial failed to meet its primary end point.

Personalizing treatment options and setting realistic expectations are crucial.

Compensation techniques in swept-source optical coherence tomography angiography improve accuracy by correcting signal loss from drusen and other artifacts

Researchers introduce a multistage dual-branch network to improve accuracy and efficiency

In the European Union and United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular edema

Below a specific threshold, FCP exerts a protective effect, but above that threshold the protective effect becomes uncertain.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

The new data builds upon previously reported 6- and 12-month positive results from adult patients treated in the same study.

BRIMOCHOL PF’s combination of brimonidine and carbachol produces a “pinhole effect,” which is intended to improve depth of focus and sharpen near and distant impact.

Katrina Ronne shares her vision to empower ophthalmologists, champion equity, and strengthen advocacy for better eye health outcomes across Australia.

Although it improved interdisciplinary communication, ongoing review and safety monitoring are necessary for successful clinical implementation.

A study found that children with early-onset atopic dermatitis have a higher risk of developing uveitis and should be closely monitored for its onset.

Each company will hold a respective special meeting of stockholders to vote on the approval of the merger.

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment

Tapcom is a preservative-free, fixed-combination eye drop of tafluprost 0.0015% and timolol 0.5% for lowering intraocular pressure.

In celebration of Ophthalmology Times' 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the past 5 decades.

The novel corrective eye drop can be prescribed through pharmacy partners BlinkRx or Medvantx

Researchers from the Czech Republic found that an AI system showed higher sensitivity and specificity for screening diabetic retinopathy compared to telemedicine evaluations.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

Tertiary syphilis, which can develop years to decades after the initial infection, is characterized by chronic inflammatory damage affecting multiple organ systems.

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest innovation in ophthalmology in the last 5 decades.

Recent estimates show that there are over 2 billion users on Instagram, of which over 726.8 million interact with reels on the platform.

Uveal melanoma, which primarily affects Caucasian patients, is the most common primary intraocular tumor in adults2 that most often affects the choroid (90%), ciliary body (6%), and iris (4%)

The trial is designed to assess the safety and effectiveness of Avisi Technologies' investigational VisiPlate device in patients with open-angle glaucoma.